Holistic Value Assessment of Tirbanibulin for Actinic Keratosis: European Multi-Criteria Decision Analysis
Overall, participants recognized tirbanibulin as a valuable treatment for AK, on the basis of robust evidence, favorable safety/tolerability and patient-reported outcomes (PRO) profiles, and alignment with clinical guidelines, with similar efficacy compared with 5FU-4%.
Authors
- Eggert Stockfleth (ORCID: https://orcid.org/0000-0002-1922-9062)
- Arianna Petracca
- José Luis Trillo
- Elvira Moscarella
- Giovanna Gambarelli
- Julio Sosa
- Carola Berking
- Josep Malvehy
- Gregorio Romero
- Andrea Carugno
- Rafael Botella
Institutions
- University of Insubria (IT)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Campania "Luigi Vanvitelli" (IT)
- Generalitat Valenciana (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Universitätsklinikum Erlangen (DE)
- Consorci d’Atenció Primària de Salut Barcelona Esquerra (ES)
- Hospital de Hellín (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s13555-026-01689-y
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00